SANUWAVE Health, Inc.

SANUWAVE Health, Inc. entered into Amendment No. 1 to its Credit Agreement and Waiver. The amendment includes a waiver from lenders for a default related to the fixed charge coverage ratio for the twelve-month period ending September 30, 2026. Additionally, lenders now require written consent for Permitted Acquisitions and Restricted Payments used for equity repurchases. The limits for permitted other secured indebtedness and subsidiary investments were each reduced from $500,000 to $250,000. The company paid a $5,000 amendment fee.

SANUWAVE Health, Inc. announced its Q2 2026 financial results, reporting a 3% decrease in revenue to $9.7 million and a net loss of $0.7 million, a significant decline from net income in the prior year. The company also reported a GAAP operating loss and a substantial drop in Adjusted EBITDA. Citing challenging market conditions and uncertainty around Medicare reimbursement developments, SANUWAVE withdrew its fiscal year 2026 guidance and plans to vigorously contest the proposed CMS rule for 2027 97610 reimbursement.

Sanuwave Health reported Q2 2026 revenues of $9.7 million, a 3% decrease year-over-year, and a GAAP operating loss of $(0.3) million, down from $1.4 million income in Q2 2025. The company also posted a net loss of $0.7 million and a decline in Adjusted EBITDA to $1.2 million. Despite a challenging market, Ultramist applicator revenue increased by 13%, though system sales were negatively impacted by CMS reimbursement changes and a growing market for used systems. Due to ongoing market uncertainty and proposed CMS reimbursement changes for 2027, Sanuwave has withdrawn its previously issued fiscal year 2026 guidance.

SANUWAVE Health, Inc. reported a net loss of $0.68 million for Q2 2026, a shift from a net income of $0.55 million in the prior year's quarter. For the first six months of 2026, the company's net loss narrowed to $2.12 million from $5.57 million in H1 2025, despite a slight revenue decrease to $19.36 million. Operating cash flow significantly improved, turning positive at $0.82 million for H1 2026. The company also continued to address previously disclosed restatements related to sales tax liabilities and warranty accounting.

Sanuwave Health, Inc. announced it will host a live conference call on Friday, August 7, 2026, at 8:30 AM ET to present its second-quarter 2026 financial results. Participants can access the call via dial-in numbers or a live webcast. Materials for the conference call will be available on the company's website, and a replay will be accessible until August 21, 2026.

Sanuwave Health, Inc. announced preliminary, unaudited revenues for the second quarter of 2026 are expected to be in the range of $9.6 million to $9.8 million. This figure is above the high end of the company's revised guidance of $8.5 million to $9.5 million. However, it represents a decrease of approximately 3-5% from revenues of $10.1 million in the second quarter of 2025. Despite headwinds in capital sales, the company reported record sales for consumable applicators, indicating a promising trend for its business model.

Sanuwave Health, Inc. expects preliminary second quarter 2026 revenues to be between $9.6 million and $9.8 million, exceeding the revised guidance of $8.5 million to $9.5 million. This represents a 3-5% decrease from Q2 2025 revenues of $10.1 million. While capital sales faced headwinds, consumable applicator sales achieved record highs in both unit sales and revenue, indicating a promising trend for future growth.

Sanuwave Health, Inc. updated its revenue guidance for the second quarter of 2026 to a range of $8.5 million to $9.5 million, which is below previous expectations. This revision is attributed to significant market disruption impacting Ultramist system sales, including widespread CMS reimbursement clawbacks and the availability of used systems from closing wound care practices. Despite these challenges, the company anticipates record unit sales for applicators in Q2.

SANUWAVE Health, Inc. reported Q1 2026 revenues of $9.6 million, a 3.1% increase year-over-year, marking the highest Q1 revenues in company history. Despite the revenue growth, the company posted a GAAP operating loss of $1.1 million, a significant swing from an operating income of $0.6 million in Q1 2025, and gross margin declined to 77.3%. However, net loss improved to $1.4 million from $6.1 million in the prior year, largely due to non-cash items. The CEO noted a market recovery starting in February and expressed optimism, with the company providing positive revenue guidance for Q2 and reiterating full-year 2026 guidance.

SANUWAVE Health, Inc. reported a net loss of $1.44 million for the first quarter of 2026, a significant improvement from the $6.12 million net loss in Q1 2025. Revenue increased by 3.1% to $9.62 million. The company also restated its Q1 2025 financial statements due to errors in sales tax liabilities and extended warranty revenue recognition, which increased the previously reported net loss for that period. Additionally, SANUWAVE modified its headquarters lease, expanding the property and extending the term.